Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Short Title: S2104

Enrollment Status: Recruiting

NCT #: NCT05040360

Specialty Area: Oncology

Condition Studied: Pancreatic Neuroendocrine Cancer

Age Groups: Adult; Older Adult

Phase: II

Study Information

Summary / Purpose

To evaluate whether giving capecitabine and temozolomide after surgery can reduce the risk of recurrence in patients with high-risk, well-differentiated pancreatic neuroendocrine tumors.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with resected, well-differentiated pancreatic neuroendocrine tumor(s)
Classified as high-risk for recurrence based on tumor features
Must have undergone curative-intent surgery
Adequate organ function and performance status
No prior chemotherapy for pancreatic neuroendocrine tumor(s)

What's Involved

Participation in the study will include:

Chemotherapy given orally with capecitabine and temozolomide after surgery
Treatment given in cycles (specific schedule per protocol)
Regular CT or MRI scans to monitor for cancer recurrence
Blood tests to check your health and how the treatment is working

Principal Investigator

Alicia Gingrich, MD

Surgical Oncology

A Member of

(775) 982–6270

Renown Surgery Care

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT05040360

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews